Erika P. Hamilton

Nov 19, 2024 | targetedonc.com | Erika P. Hamilton

Erika P. Hamilton, MD, director of breast cancer and gynecologic cancer research at the Sarah Cannon Research Institute, discusses antibody-drug conjugates (ADCs) in multiple types of breast cancer, and when to use these drugs in sequence. ADCs such as datopotamab deruxtecan (Dato-DXd), trastuzumab deruxtecan (Enhertu), and sacituzumab govitecan (Trodelvy) have been studied across breast cancer subgroups.

Oct 31, 2024 | targetedonc.com | Erika P. Hamilton

Erika Hamilton, MD, director of Breast Cancer Research at the Sarah Cannon Research Institute, discusses how important it is to continue targeting ER after progression on endocrine therapy in patients with breast cancer. She then highlights the available treatment options for patients who progress on CDK4/6 inhibitors and the next steps for research in this space. Transcription:0:09 | It is really important. There are many patients whose tumors continue to be sensitive to endocrine agents.

Oct 30, 2024 | targetedonc.com | Erika P. Hamilton

Erika Hamilton, MD, director of Breast Cancer Research at the Sarah Cannon Research Institute, discusses how to approach treatment after progression on first-line therapy and hormone receptor-positive breast cancer. Hamilton explains that the approach to treating breast cancer with endocrine therapies has become increasingly complex. There are now several actionable steps depending on specific genetic mutations.

Oct 28, 2024 | targetedonc.com | Erika P. Hamilton

Erika Hamilton, MD, director of Breast Cancer Research at the Sarah Cannon Research Institute, discusses the different classes of endocrine therapies and how they compare to one another.

Oct 25, 2024 | targetedonc.com | Erika P. Hamilton

Erika Hamilton, MD, director of Breast Cancer Research at the Sarah Cannon Research Institute, discusses how novel endocrine therapies improve treatment for metastatic breast cancer. She also discusses what upcoming developments in the breast cancer space she is most excited about. Transcription:0:09 | What we are seeing is that CDK4/6’s are really the mainstay of our treatment. In the first-line, they extended progression-free survival by almost a year, improving overall survival in many cases.